alexa
Reach Us +44-1647-403003
Promising Pre-clinical Validation of Targeted Radionuclide Therapy Using a [131I] Labelled Iodoquinoxaline Derivative for an Effective Melanoma Treatment | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Promising Pre-clinical Validation of Targeted Radionuclide Therapy Using a [131I] Labelled Iodoquinoxaline Derivative for an Effective Melanoma Treatment

Bonnet-Duquennoy M1*, Papon J1, Mishellany F2, Denoyer D1, Labarre P1, Guerquin-Kern JL3,4, Penault-llorca F2, Madelmont JC1, Miot-Noiraulte E 1, Cayre A2, Chezal JM1, Moins N1

1Clermont Université/ Univ Clermont 1, EA 4231/ Clermont-Ferrand, BP 184, F-63001 France

2Centre Jean Perrin, Laboratoire d’anatomo-pathologie, Clermont-Ferrand, F-63011, France

3Institut Curie, Laboratoire de Microscopie Ionique, 91405 Orsay, France

4Inserm, U759, 91405 Orsay, France

*Corresponding Author:
Dr. Bonnet -Duquennoy M
Clermont Université/ Univ Clermont 1
EA 4231/ Clermont-Ferrand, BP 184
F- 63001, France,
E-mail: [email protected]

Received Date: October 28, 2009; Accepted Date: November 27, 2009; Published Date: November 27, 2009

Citation: Bonnet-Duquennoy M, Papon J, Mishellany F, Denoyer D, Labarre P, et al. (2009) Promising Pre-clinical Validation of Targeted Radionuclide Therapy Using a [131I] Labelled Iodoquinoxaline Derivative for an Effective Melanoma Treatment. J Cancer Sci Ther 1: 001-007. doi:10.4172/1948-5956.1000001

Copyright: © 2009 Bonnet-Duquennoy M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Targeted internal radionuclide therapy (TRT) would be an effective alternative to current therapies for disseminated melanoma treatment. At our institution, a class of iodobenzamides has been developed as potent melanomaseeking agents. This review described the preclinical validations of a quinoxaline derivative molecule (ICF01012) as tracer for TRT application. It was selected for its high, specific and long-lasting uptake in tumour with rapid clearance from non-target organs providing suitable dosimetry parameters for TRT. Extended in vivo study of metabolic profiles confirmed durable tumoural concentration of the unchanged molecule form. Moreover melanin specificity of ICF01012 was determined by binding assay with synthetic melanin and in vivo by SIMS imaging. Then, we showed in vivo that [131I] ICF01012 treatment drastically inhibited growth of B16F0, B16Bl6 and M4Beu tumours whereas [131I] NaI or unlabelled ICF01012 treatment was without significant effect. Histological analysis showed that residual tumour cells exhibit a significant loss of aggressiveness after treatment. This anti-tumoural effect was associated with a lengthening of the treated-mice survival time and an inhibition of lung dissemination for B16Bl6 model. Results presented here support the concept of TRT using a [131I] labelled iodoquinoxaline derivative for an effective melanoma treatment.

Share This Page
Top